Sort
21,281 grants matching “influenza”
Influenza Immunity: Protective Mechanisms Against Pandemic Respiratory Virus
$1,600,000Mark M Davis · Stanford University · U19 · FY2009 · AI
Annual Estimates of Influenza Vaccine Effectiveness and Evaluation of Immune Response in a Wisconsin Population
$1,600,000Edward Belongia · Marshfield Clinic Research Foundation · U01 · FY2018 · IP
Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse network
$1,600,000Richard K Zimmerman · University Of Pittsburgh At Pittsburgh · U01 · FY2018 · IP
Harnessing Human DC Subsets for Improved Muscosal Vaccines
$1,600,000Jacques F Banchereau · Baylor Research Institute · U19 · FY2009 · AI
INFLUENZA OR FLU IS ONE OF TOP 3 ECONOMIC DISEASES AFFECTING THE PORK INDUSTRY. IN HUMANS, IT CAUSES UP TO 41,000 HUMAN FATALITIES IN UNITED STATES AND UPWARDS OF 500,000 CASUALTIES WORLDWIDE. PIGS SERVE AS RESERVOIRS FOR SWINE, AVIAN, AND HUMAN VIRUSES AND PRODUCE NOVEL HIGH POTENCY STRAINS, SIMILAR TO THE "SWINE FLU" PANDEMIC H1N1 STRAIN. OUR HYPOTHESIS IS THAT ELIMINATING RECEPTORS FOR VIRAL ENTRY AND INTERFERING WITH VIRAL REPLICATION WILL SERVES AS A DUAL MECHANISM FOR PROTECTING THE PIGS FROM VIRAL INFECTION, AND TRANSMISSION OF FLU TO HUMAN AND PIG HOSTS. THERE ARE THREE OBJECTIVES IN THE PROPOSAL: 1) ASSEMBLE AND VALIDATE GENOME EDITING TOOLS TO DELETE THE RECEPTOR FOR FLU VIRUS ENTRY, AND PREVENT VIRAL PROPAGATION; 2) GENERATE RECOMBINANT PIGS; AND 3) TEST THE RECOMBINANT PIGS FOR SUSCEPTIBILITY TO INFECTION BY SWINE AND HUMAN TYPE ADAPTED VIRUSES TO INFECTION AND DISSEMINATION. WE EXPECT TO DEVELOP A PIG MODEL OF INFLUENZA RESEARCH AND IDENTIFY DRUGGABLE TARGETS. FROM AGRICULTURAL STAND POINT, WE ANTICIPATE ELIMINATION OF FLU FROM COMMERCIAL SWINE HERDS.
$1,600,000University Of Maryland, College Park · · FY2015 · National Institute of Food and Agriculture
Emerging infections: surveillance, epidemiology and pathogenesis
$1,598,955David Wang · Washington University · U01 · FY2023 · AI
DEVELOPMENT OF INFLUENZA SURVEILLANCE NETWORKS
$1,598,774A.c Mishra · Indian Council Of Medical Research · U50 · FY2006 · CI
Rapid point-of-care diagnostic for bioterrorism "A" agents and Pandemic influenza
$1,597,233Kelly J. Henrickson · Medical College Of Wisconsin · U01 · FY2007 · AI
Mouse Models for Understanding Host Responses to Intracellular Pathogens
$1,595,854Ellen A Robey · University Of California Berkeley · P01 · FY2009 · AI
Collaborative Influenza Vaccine Innovation Centers STATISTICAL, DATA MANAGEMENT AND COORDINATION CENTER (SDMCC)
$1,595,761Stephan Bour · Digital Infuzion, Inc. · N01 · FY2024 · AI
NIAID Centers of Excellence for Influenza Research and Response (CEIRR): Avian Influenza Research Activities
$1,595,368Anice Lowen · Emory University · N01 · FY2025 · AI
Mechanisms and Enviromental Determinants of Rhinovirus Illness Severity
$1,595,171James E. Gern · University Of Wisconsin-Madison · U19 · FY2014 · AI
Human Mab Cocktails to Prevent & Treat H5N1 Avian Influenza
$1,594,408Wayne A. Marasco · Dana-Farber Cancer Inst · U01 · FY2007 · AI
Aging and Immunity to Infections
$1,593,959Susan L Swain · Trudeau Institute, Inc. · P01 · FY2006 · AG
Toward a Universal Influenza Virus Vaccine
$1,592,593Peter Palese · Icahn School Of Medicine At Mount Sinai · P01 · FY2013 · AI
Dynamics and Evolution of Immune Responses to Influenza Viruses
$1,591,719Rustom Noshir Antia · Emory University · U19 · FY2016 · AI
Comparative Study of Influenza Vaccines in Adults
$1,589,316University Of Michigan At Ann Arbor · U01 · FY2005 · AI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
$1,587,976Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Modeling affinity maturation at molecular resolution
$1,587,693Thomas B Kepler · Boston University Medical Campus · U19 · FY2016 · AI
Dynamics and Evolution of Immune Responses to Influenza Viruses
$1,587,645Rustom Noshir Antia · Emory University · U19 · FY2017 · AI
Adjuvant Enhanced Antiviral Immunity
$1,586,243Jeff C Fairman · Juvaris Biotherapeutics, Inc. · U01 · FY2008 · AI
Vaccine Treatment Evaluation Units(VTEU) mRNA-1273-P204 Moderna Pediatric
$1,585,845Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2021 · AI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)
$1,585,602Walter A. Orens · Emory University · N01 · FY2020 · AI
Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell Transplant Recipients
$1,584,794Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2018 · AI
Novel Chemical and Immunological Approaches to Influenza Therapy
$1,583,376Michael B Oldstone · Scripps Research Institute, The · U01 · FY2008 · AI